Decline In Ad Letters Does Not Signal Leniency By FDA, Agency Says
This article was originally published in The Pink Sheet Daily
FDA is using warning letters to "presage," not "replace" enforcement action, Associate Commissioner Pitts tells DTC National Conference in Boston.
You may also be interested in...
A professional sales aid and the product website fail to include contraindications and warnings for the drug’s decongestant component pseudoephedrine, an FDA ad division letter states.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.